



# The Canadian Vaccine Catalogue

**Monthly Working Group Meeting**

November 27, 2020

# Attendees

---

- Abhi Kalbra, Canada Health Infoway
- Andrea MacLean, Canada Health Infoway
- Arielle Goldman Smith, Shared Health Manitoba
- Ashish Kumar, Shared Health Manitoba
- Cameron Bell, CANImmunize
- Celine O'Brien, Government of Alberta
- Chris Bell, PHAC
- Dennis Sharkey, BCCDC
- Dr. Kumanan Wilson, CANImmunize
- Dr. Sarah Wilson, Public Health Ontario
- Helen Xing, BCCDC
- Jennifer Omega, Shared Health Manitoba
- Kari Bergstrom, Government of Alberta
- Lori Kane, Ministry of Health Ontario
- Marc L'Arrivee, Shared Health Manitoba
- May Canning, BCCDC
- Melanie Reed, Health Canada
- Nicolas Gilbert, PHAC
- Sherri Boucher, Health Canada
- Taylor Rubens-Augustson, CANImmunize


# Agenda

Objective: To determine what role the public health community is looking to the Canadian Vaccine Catalogue to play in the rollout of the COVID-19 vaccines in Canada.

- About the CVC and CVC Working Group
- What will be required from the CVC to support the COVID-19 vaccine rollout?
- Update from Canada Health Infoway
- Proposed COVID-19 concepts
- Next steps
- Questions/Discussion
- Overview of CVC 1.1.6 Release

# What is the CVC?

- The Canadian Vaccine Catalogue (CVC) is the comprehensive, standards-based source-of-truth resource for vaccine terminology and vaccine product information in Canada.
- Supported by Canada Health Infoway, and previously by the Ontario MOHLTC and PHAC. Developed and maintained by CANImmunize.
- Used in BC and ON to configure their provincial immunization repositories, as well as by other jurisdictions to some extent.



# About the CVC Working Group

- The CVC WG manages the release cycle and content of the CVC.
- Has been the primary contributor of content to the Pan-Canadian Immunization Reference Sets.
- The WG is open to immunization stakeholders from all Canadian jurisdictions/agencies/committees/vendors.
- The WG meets at least once per month to discuss the following (but not limited to):
  - New/upcoming vaccine products on the market
  - Changes to existing products/discontinued products
  - Requests for Change (RFCs)
  - Quality assurance processes
- Our hope is to increase engagement in the WG and bring other F/P/T stakeholders on board.

# CVC Release Schedule

	Nov 2020	Dec 2020	Jan 2021	Feb 2021	Mar 2021	Apr 2021	May 2021	Jun 2021	Jul 2021	Aug 2021
Lot data received from Health Canada	02-Nov-20	01-Dec-20	04-Jan-21	01-Feb-21	01-Mar-21	01-Apr-21	03-May-21	01-Jun-21	01-Jul-21	02-Aug-21
<b>Target release</b>	<b>12-Nov-20</b>	<b>11-Dec-20</b>	<b>14-Jan-21</b>	<b>11-Feb-21</b>	<b>11-Mar-21</b>	<b>13-Apr-21</b>	<b>13-May-21</b>	<b>11-Jun-21</b>	<b>13-Jul-21</b>	<b>12-Aug-21</b>
Release finalized, including lot data incorporated, release promoted to QA	5-Nov-2020	4-Dec-2020	7-Jan-2021	4-Feb-2021	4-Mar-2021	6-Apr-2021	6-May-2021	4-Jun-2021	6-Jul-2021	5-Aug-2021
Stakeholder call: overview of changes	29-Oct-2020	27-Nov-2020	31-Dec-2020	28-Jan-2021	25-Feb-2021	30-Mar-2021	29-Apr-2021	28-May-2021	29-Jun-2021	29-Jul-2021
CVC release sent to stakeholders	22-Oct-2020	20-Nov-2020	24-Dec-2020	21-Jan-2021	18-Feb-2021	23-Mar-2021	22-Apr-2021	21-May-2021	22-Jun-2021	22-Jul-2021
Prerelease preparation	15-Oct-2020	13-Nov-2020	17-Dec-2020	14-Jan-2021	11-Feb-2021	16-Mar-2021	15-Apr-2021	14-May-2021	15-Jun-2021	15-Jul-2021
RFC submission deadline	17-Sep-2020	16-Oct-2020	19-Nov-2020	17-Dec-2020	14-Jan-2021	16-Feb-2021	18-Mar-2021	16-Apr-2021	18-May-2021	17-Jun-2021

\* Ad hoc releases will be added as needed to ensure COVID-19 content is available in a timely manner.

# Sign Up for Notifications of CVC Releases

<https://bit.ly/3fKt8HZ>

# Developing COVID-19 Vaccine Terminology and Standards

- Ensuring that Canada has standardized terminology and data standards for tracking the COVID-19 vaccines will be essential.
- Several stakeholders have reached out to the CVC team inquiring about when this content will become available in the CVC.
- Some jurisdictions have already started the process of setting up COVID-19 terminology in their repository systems, but are waiting on concept codes.

# Developing COVID-19 Vaccine Terminology and Standards

- The CVC team and working group is prepared to lead the effort to develop and publish the necessary COVID-19 vaccine terminology:
  - We will need to convene regular working group meetings.
  - We will require information and expertise from:
    - PHAC
    - Health Canada
    - NACI
    - P/T Stakeholders
    - Infoway Terminologists
  - All SNOMED CT terminology will need to be published through Terminology Gateway.
  - Working group meetings and stakeholder engagement will be managed through PHS community on InfoCentral so that everyone can participate.
  - **Target date:** CVC Release in early January should contain tradename concepts for Pfizer and Moderna vaccines.

# Question Set 1

Is anyone else doing this work already?

Is the CVC working group the right table for this work to be done?

Would it make sense to formalize the CVC working group as a subcommittee under the Canadian Immunization Registries and Coverage Network (CIRC)?

Update from Canada Health Infoway (Andrea MacLean)

# Proposed COVID-19 Concepts

Concept	Infoway Concept Status	CVC Publication Target
<b>Disease</b>	<a href="#">RFC completed</a> , in scope for March 2021 CA Edition publication.	In scope for Dec. 11 2020 release.
<b>Antigen</b>	<a href="#">RFC completed</a> , in scope for March 2021 CA Edition publication.	In scope for Dec. 11 2020 release.
<b>Generic Agent Unspecified</b>	<a href="#">RFC in progress</a> , submitted to IHTSDO.	Release date decision waiting on code approval.
<b>More granular generic agents</b>	More information/discussion needed.	
<b>Tradename - Pfizer Vaccine</b>	Placeholder RFC submitted, more information/discussion needed.	TBD. Needs to allow sufficient time for configuration in repositories.
<b>Tradename - Moderna Vaccine</b>	Placeholder RFC submitted, more information/discussion needed.	TBD. Needs to allow sufficient time for configuration in repositories.
<b>Tradename - Future Products</b>	CVC WG will submit RFCs as product information is made available.	CVC will aim to publish as soon as possible to maximize time for configuration in repositories.

# Disease Concept

- A concept is present in SNOMED International and the Canadian Edition - RFC completed to add it to Pan-Canadian Reference Set
- 840539006 | Disease caused by Severe acute respiratory syndrome coronavirus 2 (disorder)|
- Added to VaccinePreventableDiseaseCode Subset
- In scope for the March 2021 CA Edition publication
- In scope for December 11th CVC release

# Antigen Concept

- A concept is present in SNOMED International and the Canadian Edition - RFC completed to add it to Pan-Canadian Reference Set
- 840536004 |Antigen of Severe acute respiratory syndrome coronavirus 2 (substance)|
- Added to AntigenCode Subset
- In scope for the March 2021 CA Edition publication
- In scope for December 11th CVC release

# Generic Agent Unspecified

- Concept created in CA Edition in scope for the March 2021 CA Edition publication
- ConceptID: 28531000087107
- FSN: Vaccine product against disease caused by Severe acute respiratory syndrome coronavirus 2 (medicinal product)
- PT: COVID-19 unspecified
- Syn: Novel coronavirus vaccine
- Syn: Vaccine against COVID-19
- Syn: Vaccine product against disease caused by Severe acute respiratory syndrome coronavirus 2
- Syn: Vaccine product for prevention of disease caused by Severe acute respiratory syndrome coronavirus 2

## Question 2

Is a more generic mRNA spike-protein COVID-19 vaccine concept needed?

- Would be useful for historical documentation of an immunization if the patient knows when they received a COVID-19 vaccine and this date was prior to the release of a non-mRNA vaccine?

## Question 3

Does PHAC or Health Canada have the information needed to submit RFCs to Infoway for the vaccine trade name concepts?

### Information needed:

- Trade Name Strength Dose Form Manufacturer or Marketing Authorization Holder (MAH) (product)
- e.g.: Avaxim 80 units per 0.5 milliliter suspension for injection Sanofi Pasteur Limited (product)
- Reference material (publicly available, authoritative, recent and relevant)
- This is usually obtained from a Product Monograph. When do we expect this to be available?
- For Infoway: will it be possible to have a code created prior to a Product Monograph being available?

## Question 4

Are there concepts the P/Ts anticipate needing that are not included in our list above?

## Question 5

What amount of time is needed for P/Ts to configure their repositories?

Notes:

- Additions to the Canadian SNOMED CT extension won't be formally published until March 2021, but CVC will pre-adopt concepts so they are available to systems in a timely manner.
- The concept codes will be available as soon as they are approved by IHTSDO. P/Ts not integrating with the CVC APIs will be able to start preparing the codes in their system as this time, however changes could occur up until the time the CVC is published.

# Lot Numbers and Expiry Dates

- Health Canada already provides monthly lot release extracts to the CVC.
- Health Canada has verbally indicated they will be able to provide ad hoc reports of newly released lots of COVID-19 vaccine.

## **Question for Health Canada:**

Is there anything needed to formalize this data flow to ensure the CVC can rely on this for COVID-19 lot information?

# GTINs and Barcode Scanning

- The CVC now has access to the GS1 ECCnet database (as VIDS did).
- There is work underway to get manufacturers to report this information to CANImmunize (outreach campaign in collaboration with GS1).
- We could also manually load GTIN numbers if the vendor has assigned these but it not yet reporting them through ECCnet.

## **Question for PHAC:**

Could PHAC request that the vendors upload GTIN data into ECCnet and publish this information to CANImmunize, so that it can be included in the CVC?

# Next Steps

- Establish CVC working group's role in development of COVID-19 vaccine terminology.
- If CVC WG is to lead this work, we will start weekly meetings managed through PHS InfoCentral community to engage stakeholders from across the country.
- We will be aiming for a late December release of tradename concepts for the Pfizer and Moderna vaccines.

# Questions/Discussion/Updates

# CVC Version 1.1.6

## Completed RFCs

- FLUCELVAX QUAD (tradenname addition)
- Add Disease caused by SARS-CoV-2 concept to VaccinePreventableDiseaseCode subset
- Add Antigen of SARS-CoV-2 concept to AntigenCode Subset

## Updates - GTIN Data

- Working with GS1 to gain access to GS1 data - outreach campaign to manufacturers
- Article to be published in collaboration with GS1 about how GTIN data is used for vaccines

# RFC Request 1 - BC

1. Update existing trade name GamaSTAN@(concept code 19391000087103, DIN 02230579) to GamaSTAN S/D
2. Add new code for trade name GamaSTAN (DIN 02486598)

Reasoning: Based on DPD search result below, existing CVC item's trade name doesn't match (circled in yellow). New code need to be added for product circled in green. BCY will be receiving new product (DIN 02486598) soon, as existing product (DIN 02230579) will be phased out.

## List of returned drug products

Status	DIN	Company	Product	Class	PM 1	Schedule	# 2	A.I. name 3	Strer
Cancelled Post Market	<a href="#">00083259</a>	CUTTER MED & BIOL, DIVISION OF MILES CANADA LTD.	GAMASTAN	Human	No	Schedule D	1	IMMUNOGLOBULIN (HUMAN)	16.5 %
Marketed	<a href="#">02486598</a>	GRIFOLS THERAPEUTICS LLC	GAMASTAN	Human	Yes	Schedule D	1	IMMUNOGLOBULIN (HUMAN)	18 %
Marketed	<a href="#">02230579</a>	GRIFOLS THERAPEUTICS LLC	GAMASTAN S/D	Human	Yes	Schedule D	1	IMMUNOGLOBULIN (HUMAN)	18 %

# RFC Request 2 - BC

- BCY have received a request from Inventory business on adding a new flu vaccine that is a German product, available in US.
- Need to completed configuration in Panorama in the next 2, 3 weeks.
- This product is being brought into Canada by Health Canada using the UPHN urgent public health need process, hence the different code in DIN field.
- This vaccine will likely be used by multiple provinces in Canada for this flu season.
- We need this to be added in CVC to support interfaces.

## Details from BC Inventory Manager (Tradename updated)

Immunizing Agent (L2)	Product Trade Name (L6)	Manufacturer Code (L6)	Presentati on Type (L4)	Presentati on Volume (L4)	Presentati on Volume Unit of Measure (L4)	Typic al Dose Size (L3)	Typical Dose Size Unit of Measure (L3)	Packa ge Size (L5)	Route of Administration (L4)	Item DIN (L6)
Influenza-Inactiv ated	INFLUSPLIT TETRA	GlaxoSmithKlin e	Syringe	0.50	mL	0.50	mL	1	Intramuscular	PEI.H.11629.01.1

# Wrap Up

Upcoming release dates:

- Friday, December 4th: Release finalized and sent to stakeholders for review (with high-level summary)
- Friday, December 11th: Target release date